Journal profile · PHARMACOLOGY & PHARMACY
Future Journal of Pharmaceutical Sciences
ISSN 2314-7245 · eISSN 2314-7253 · SpringerOpen · United Kingdom
Future Journal of Pharmaceutical Sciences: CAS Zone 4 · Medicine (2025 upgraded edition); fully open access; APC about USD 2,190; review about 23 weeks (community reports); 165 articles in 2025; indexed in ESCI.
Scope
Aims, scope and focus
Future Journal of Pharmaceutical Sciences is published by SpringerOpen and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Analytical Methods in Pharmaceuticals, Advanced Drug Delivery Systems and Essential Oils and Antimicrobial Activity, together about 23.5% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
Read the latest articles of Future Journal of Pharmaceutical Sciences at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Analytical Methods in PharmaceuticalsChemistry9.9%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics7.1%
- Essential Oils and Antimicrobial ActivityAgricultural and Biological Sciences6.5%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics6.4%
- Analytical Chemistry and ChromatographyChemistry6.4%
- Computational Drug Discovery MethodsComputer Science5.8%
- Phytochemistry and Biological ActivitiesAgricultural and Biological Sciences5.1%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- h-index
- 58OpenAlex ·
- i10-index
- 471OpenAlex ·
- 2-year mean citedness
- 6.02OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 164LetPub ·
Articles by year OpenAlex count · 1,083 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 91 | 91 | 45 |
| 2025 | 165 | 165 | 597 |
| 2024 | 178 | 178 | 1,972 |
| 2023 | 121 | 121 | 1,691 |
| 2022 | 61 | 61 | 1,245 |
| 2021 | 240 | 240 | 5,992 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 23 weeksLetPub ·
- Submission to publication (journal-reported)
- about 23 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 1,890 / USD 2,190 / GBP 1,590 | Yes | CC BY | |
| OpenAlex | USD 0 | — | — | |
| LetPub | No APC | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- SpringerOpen
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2314-7245
- Electronic ISSN
- 2314-7253
- Official links
- Journal homepage ↗OpenAlex
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Future Journal of Pharmaceutical Sciences
What CAS zone is Future Journal of Pharmaceutical Sciences in?
In the 2025 upgraded edition of the CAS Journal Ranking, Future Journal of Pharmaceutical Sciences is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Future Journal of Pharmaceutical Sciences?
Authors report an average review time of about 23 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Future Journal of Pharmaceutical Sciences?
According to LetPub and DOAJ records, Future Journal of Pharmaceutical Sciences is indexed in ESCI and DOAJ.
Is Future Journal of Pharmaceutical Sciences open access, and what is the APC?
Future Journal of Pharmaceutical Sciences is a fully open-access journal. APC about USD 2,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .